MARKET

BBIO

BBIO

Bridgebio Pharma
NASDAQ
63.30
-2.45
-3.73%
After Hours: 64.26 +0.96 +1.52% 19:51 10/13 EDT
OPEN
66.05
PREV CLOSE
65.75
HIGH
66.05
LOW
62.94
VOLUME
2.71M
TURNOVER
--
52 WEEK HIGH
93.42
52 WEEK LOW
52.75
MARKET CAP
12.37B
P/E (TTM)
-17.7385
1D
5D
1M
3M
1Y
5Y
1D
BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews
Seeking Alpha · 13h ago
BridgeBio Wins FDA Priority Review for Infigratinib
TipRanks · 16h ago
BridgeBio Pharma (BBIO) Gains Clinical Momentum, Is The Upside Already Priced In?
Simply Wall St · 21h ago
Weekly Report: what happened at BBIO last week (1005-1009)?
Weekly Report · 1d ago
BridgeBio Reports Encaleret Gains In ADH1; Starts RECLAIM-HP Phase 3 In Chronic Hypoparathyroidism
NASDAQ · 1d ago
Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care
Benzinga · 1d ago
Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations
Benzinga · 1d ago
BridgeBio Highlights Attruby Data Showing Lower Hospitalization Risk In ATTR-CM At HFSA 2026
NASDAQ · 1d ago
More
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Webull offers BridgeBio Pharma Inc stock information, including NASDAQ: BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBIO stock methods without spending real money on the virtual paper trading platform.